Pfeiffer Cells

Pfeiffer is a human diffuse large B-cell lymphoma (DLBCL) cell line derived from the malignant lymphoid tissue of an adult patient. It represents a mature B-cell neoplasm and grows in suspension as single cells and small aggregates under standard culture conditions. Morphologically, Pfeiffer cells display features typical of large transformed B lymphocytes, including a high nuclear-to-cytoplasmic ratio, prominent nucleoli, and dispersed chromatin. The cell line expresses B-cell-associated surface markers, including CD19, CD20, CD22, and surface immunoglobulin, consistent with its origin from germinal center or post-germinal center B cells.

At the molecular level, Pfeiffer cells harbor genetic alterations characteristic of aggressive B-cell lymphomas. These commonly include abnormalities affecting key oncogenic pathways such as BCL6 deregulation and alterations in signaling cascades involved in proliferation and survival, including NF-κB and PI3K/AKT pathways. Like many DLBCL models, Pfeiffer exhibits complex karyotypic changes and somatic mutations in genes frequently implicated in lymphomagenesis. The cell line has been included in large-scale genomic and pharmacogenomic profiling efforts, supporting its use as a representative model for studying the genetic heterogeneity and therapeutic vulnerabilities of DLBCL.

Functionally, Pfeiffer is widely used to investigate mechanisms of B-cell receptor signaling, antibody-dependent cellular cytotoxicity (ADCC), and responses to targeted agents such as anti-CD20 monoclonal antibodies, kinase inhibitors, and epigenetic modulators. Its robust CD20 expression makes it a suitable in vitro model for evaluating rituximab-mediated immune effector functions. Consequently, Pfeiffer serves as a valuable experimental system for dissecting molecular drivers of aggressive B-cell lymphoma and for preclinical testing of novel immunotherapeutic and small-molecule strategies.